Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Executive Summary
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.
You may also be interested in...
Indian Court Lifts Curbs On Herceptin Biosimilars; Roche Sticks To Guns
An Indian court has, in a seesaw turn, lifted certain restrictions pertaining to partners Biocon and Mylan’s biosimilar versions of Roche’s Herceptin (trastuzumab). Roche, though, doesn’t seem keen to back off just yet and continues to rake up issues around data requirements for biosimilars.
Indian Court Lifts Curbs On Herceptin Biosimilars; Roche Sticks To Guns
An Indian court has, in a seesaw turn, lifted certain restrictions pertaining to partners Biocon and Mylan’s biosimilar versions of Roche’s Herceptin (trastuzumab). Roche, though, doesn’t seem keen to back off just yet and continues to rake up issues around data requirements for biosimilars.
Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.